OVERALL VISION FOR DEVELOPMENTAL ACTIVITIES Over the last 5 years of our CCNE, there has been a tremendous interest by researchers to join the consortium through pilot projects and/or collaborative research. We view such projects as an important adjunct of the CCNE's mission and from which full projects and important science can emerge. For example, in the past our consortium has funded the selected following projects: ? Paula Hammond and Dane Wittrup (pilot project) on functionalized linear-dendritic diblock copolymers for tumor-selective nucleic acid delivery. One ofthe postdocs (Greg Thurber) now works in the Weissleder lab and confinues interactions (85, 86) ? Stephen Lippard (pilot project) on functionalizing gold nanoparticles with DNA duplexes containing tethered, releasable plafinum conjugates at their termini in collaboration with Chad Mirkin at Northwestern CCNE (87) ? Robert Westen/elt (pilot project) on hybrid integrated circuit/microfluidic chips forthe manipulation of cells (88, 89) ? Sridhar Ramaswamy (pilot project) on nanomodels of metastatic cancer (90) ? Mehmet Toner and Daniel Haber (pilot project) on microfluidic sorting of circulating tumor cells. This original pilot project has resulted in several high impact publications (91-93) and funding outside the consortium, including a recent SU2C grant involving several CCNE members (Bhatia, Weissleder). Pilot, Alliance Challenge and other exploratory projects provide a mechanism by which to attract new researchers and to rapidly fund the most promising ideas. The following section lists some of our general plans on continuing developmental activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151884-03
Application #
8382485
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$78,280
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Bartelt, Alexander; Widenmaier, Scott B; Schlein, Christian et al. (2018) Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity. Nat Med 24:292-303
Lim, Jong-Min; Cai, Truong; Mandaric, Stefan et al. (2018) Drug loading augmentation in polymeric nanoparticles using a coaxial turbulent jet mixer: Yong investigator perspective. J Colloid Interface Sci 538:45-50
Lo, Justin H; Hao, Liangliang; Muzumdar, Mandar D et al. (2018) iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 17:2377-2388
Chertok, Beata; Langer, Robert (2018) Circulating Magnetic Microbubbles for Localized Real-Time Control of Drug Delivery by Ultrasonography-Guided Magnetic Targeting and Ultrasound. Theranostics 8:341-357
Miller, Miles A; Askevold, Bjorn; Mikula, Hannes et al. (2017) Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun 8:15906
Mitchell, Michael J; Webster, Jamie; Chung, Amanda et al. (2017) Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis. Nat Commun 8:14179
Corbo, Claudia; Molinaro, Roberto; Tabatabaei, Mateen et al. (2017) Personalized protein corona on nanoparticles and its clinical implications. Biomater Sci 5:378-387
Shi, Jinjun; Kantoff, Philip W; Wooster, Richard et al. (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17:20-37
Arlauckas, Sean P; Garris, Christopher S; Kohler, Rainer H et al. (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9:
Bertrand, Nicolas; Grenier, Philippe; Mahmoudi, Morteza et al. (2017) Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat Commun 8:777

Showing the most recent 10 out of 170 publications